TVRD

Tvardi Therapeutics, Inc. SEC filings

Every EDGAR filing for Tvardi Therapeutics, Inc. (TVRD), newest first, with AI summaries and stories.

Ticker: TVRD
CIK: 1346830
Latest filing: Aug 14

Next: earnings expected ~Nov 13 · 10-Q expected ~Nov 16 (deadline Nov 16) · usually files the same day as earnings

Watch in the app Get the app

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

NOTABLE10-QTvardi Therapeutics, Inc.TVRDAug 14
Quarterly report
Company Filing
ROUTINE8-KTvardi Therapeutics, Inc.TVRDAug 14
Current report
Company Filing
ROUTINE8-KTvardi Therapeutics, Inc.TVRDJul 30
Current report
Company Filing
ROUTINE8-KTvardi Therapeutics, Inc.TVRDJul 17
Current report
Company Filing
ROUTINE424B5Tvardi Therapeutics, Inc.TVRDJul 17
Securities offering
Company Filing
ROUTINE8-KTvardi Therapeutics, Inc.TVRDJul 7
Current report
Company Filing
ROUTINE4Tvardi Therapeutics, Inc.TVRDJun 11
5 insider filings
Wallace L Hall Jr, insider filing for TVRD
Show all 5
- 4Insider filing for TVRDJun 11
- 4Insider filing for TVRDJun 11
- 4Insider filing for TVRDJun 11
- 4Insider filing for TVRDJun 11
- 4Insider filing for TVRDJun 11
Wallace L Hall Jr, reporting
ROUTINE8-KTvardi Therapeutics, Inc.TVRDJun 11
Current report
Company Filing
ROUTINEEFFECTTvardi Therapeutics, Inc.TVRDMay 14
Registration declared effective
Company Filing
ROUTINEEFFECTTvardi Therapeutics, Inc.TVRDMay 13
Registration declared effective
Company Filing
ROUTINEPOS AMTvardi Therapeutics, Inc.TVRDMay 8
POS AM filing
Company Filing
NOTABLE10-QTvardi Therapeutics, Inc.TVRDMay 8
Quarterly report
Company Filing
ROUTINE8-KTvardi Therapeutics, Inc.TVRDMay 8
Current report
Company Filing
ROUTINES-3Tvardi Therapeutics, Inc.TVRDMay 1
Securities offering
Company Filing
ROUTINEARSTvardi Therapeutics, Inc.TVRDApr 23
Annual report to shareholders
Company Filing
ROUTINEDEFA14ATvardi Therapeutics, Inc.TVRDApr 23
Additional proxy materials
Company Filing
ROUTINEDEF 14ATvardi Therapeutics, Inc.TVRDApr 23
Proxy statement
Company Filing
ROUTINES-8Tvardi Therapeutics, Inc.TVRDApr 1
Employee stock plan registration
Company Filing
ROUTINEPOS EXTvardi Therapeutics, Inc.TVRDApr 1
POS EX filing
Company Filing
ROUTINE424B3Tvardi Therapeutics, Inc.TVRDApr 1
Securities offering
Company Filing
NOTABLE10-KTvardi Therapeutics, Inc.TVRDMar 31
Annual report
Company Filing
ROUTINE8-KTvardi Therapeutics, Inc.TVRDMar 31
Current report
Company Filing
ROUTINE424B3Tvardi Therapeutics, Inc.TVRDMar 6
Securities offering
Company Filing
ROUTINE8-KTvardi Therapeutics, Inc.TVRDMar 6
Current report
Company Filing
ROUTINESCHEDULE 13G/ATvardi Therapeutics, Inc.TVRDFeb 17
Ownership stake disclosure by Ronald A DePinho (amended)
Company Filing
Ronald A DePinho, filed by
ROUTINE4Tvardi Therapeutics, Inc.TVRDFeb 2
4 insider filings
Avi Daniel Conn, insider filing for TVRD
Show all 4
- 4Insider filing for TVRDFeb 2
- 4Insider filing for TVRDFeb 2
- 4Insider filing for TVRDFeb 2
- 4Insider filing for TVRDFeb 2
Avi Daniel Conn, reporting
ROUTINE8-KTvardi Therapeutics, Inc.TVRDJan 16
Current report
Company Filing
ROUTINE8-KTvardi Therapeutics, Inc.TVRDDec 18, 2025
Current report
Company Filing
ROUTINE4Tvardi Therapeutics, Inc.TVRDDec 18, 2025
4 insider filings
Imran Nizamudin Alibhai, insider filing for TVRD
Show all 4
- 4Insider filing for TVRDDec 18, 2025
- 4Insider filing for TVRDDec 18, 2025
- 4Insider filing for TVRDDec 18, 2025
- 4Insider filing for TVRDDec 18, 2025
Imran Nizamudin Alibhai, reporting
ROUTINE8-KTvardi Therapeutics, Inc.TVRDNov 19, 2025
Tvardi Therapeutics, Inc. reported: Regulation FD Disclosure.
- Item 7.01. Regulation FD Disclosure.
- Item 9.01. Financial Statements and Exhibits.
Company Filing
ROUTINESCHEDULE 13G/ATvardi Therapeutics, Inc.TVRDNov 14, 2025
Ownership stake disclosure by Ronald A DePinho (amended)
Company Filing
Ronald A DePinho, filed by
ROUTINE424B3Tvardi Therapeutics, Inc.TVRDNov 13, 2025
Tvardi Therapeutics, Inc. (TVRD) filed a 424B3 prospectus supplement to register the sale of 2,084,117 shares of common stock. This filing supports the company's ongoing capital raise, providing additional funding to advance its pipeline of novel cancer therapeutics.
Company Filing
MAJOR8-KTvardi Therapeutics, Inc.TVRDNov 13, 2025
Tvardi Therapeutics, Inc. (TVRD) announced the resignation of its Chief Executive Officer, effective immediately. This unexpected leadership change could signal strategic shifts or operational challenges that investors should monitor closely, as it may impact the company's…
Company Filing
NOTABLE10-QTvardi Therapeutics, Inc.TVRDNov 13, 2025
Tvardi Therapeutics, Inc. (TVRD) filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational activities during the period.
Company Filing

Older filings on EDGAR

Get an email when Tvardi Therapeutics, Inc. files

Filings

5 insider filings

4 insider filings

4 insider filings

Tvardi Therapeutics, Inc. reported: Regulation FD Disclosure.

Tvardi Therapeutics, Inc. (TVRD) filed a 424B3 prospectus supplement to register the sale of 2,084,117 shares of common stock. This filing supports the company's ongoing capital raise, providing additional funding to advance its pipeline of novel cancer therapeutics.

Tvardi Therapeutics, Inc. (TVRD) announced the resignation of its Chief Executive Officer, effective immediately. This unexpected leadership change could signal strategic shifts or operational challenges that investors should monitor closely, as it may impact the company's…

Tvardi Therapeutics, Inc. (TVRD) filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational activities during the period.